8-K: Bausch Health: Icahn Exits Board, Paulson Boosts Stake

Bausch Health Companies Inc. announced the termination of its agreement with Icahn Group, leading to the resignation of two directors, while Paulson Capital Inc. significantly increased its shareholding.

Summary

• The Director Appointment and Nomination Agreement, dated February 23, 2021, between Bausch Health Companies Inc. and the Icahn Group, has terminated.
• This termination occurred because the Icahn Group's net long position in the company's shares fell below the required threshold.
• A supplemental letter agreement, dated May 20, 2025, also terminated.
• Brett M. Icahn and Steven D. Miller resigned from the Board of Directors, effective August 14, 2025, due to the agreement's termination.
• Mr. Miller was a member of the Audit and Risk Committee until his resignation.
• Their resignations were not due to any disagreement with the company.
• Paulson Capital Inc. and its affiliates acquired 34,721,118 common shares from the Icahn Group.
• Paulson Capital Inc. and its affiliates now beneficially own approximately 19.13% of Bausch Health's outstanding common shares as of August 15, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the departure of a significant activist investor like Icahn could be viewed negatively by some, the acquisition of their stake by the current Chairman, John A. Paulson, and his expressed confidence in the company's value and prospects, provides a positive counter-signal. The changes occurred as expected due to a pre-defined agreement.

Positives

• Paulson Capital Inc., led by the Chairperson of the Board, John A. Paulson, significantly increased its ownership to approximately 19.13% of outstanding common shares.
• John A. Paulson expressed confidence in the company's efforts to maximize shareholder value and excitement about the underlying business prospects of both Bausch Health and its subsidiary, Bausch + Lomb Corporation.
• The resignations of Brett M. Icahn and Steven D. Miller were stated not to be a result of any disagreement with the company.

Negatives

• The Icahn Group, a notable activist investor, has exited its board representation and significantly reduced its stake, potentially signaling a loss of a strong shareholder advocate.

Risks

• The press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from those described. Broader risks are detailed in Bausch Health's most recent annual and quarterly reports and other SEC/CSA filings.

Future Outlook

John A. Paulson, Chairperson of the Board, expressed belief in significant value within Bausch Health and confidence in the company's efforts to maximize shareholder value, along with excitement about the underlying business prospects of both Bausch Health and its subsidiary, Bausch + Lomb Corporation.

Management Comments

• "I believe there is significant value in Bausch Health and am confident in the Company's efforts to maximize shareholder value. I am excited about the underlying business prospects in both Bausch Health and its subsidiary, Bausch + Lomb Corporation." John A. Paulson, Chairperson of the Bausch Health Board.
• "I also want to thank Brett and Steven for their dedication and valuable contributions to the Company." John A. Paulson.

Industry Context

This announcement primarily concerns internal corporate governance and significant shareholder shifts rather than broader industry trends. It reflects a change in the company's major shareholder base and board composition, which can influence future strategic direction.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Significant change in major shareholder base with Icahn Group exiting and Paulson Capital Inc. increasing its stake, potentially influencing future strategic direction and shareholder advocacy.
• Board of Directors: Two directors appointed by the Icahn Group have resigned, altering the composition of the Board and its Audit and Risk Committee.

Next Steps

• Bausch Health's stated ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees, and investors.
• The company will continue its efforts to maximize shareholder value.

Key Dates

Recommendation

This filing primarily details a change in significant shareholding and board composition, rather than financial performance. While the exit of an activist investor like Icahn could be viewed with caution, the simultaneous increase in stake by the current Chairman, John A. Paulson, and his expressed confidence in the company's value, provides a counterbalancing positive signal. Without specific financial results or strategic shifts, a "hold" recommendation is appropriate as the immediate impact is more about ownership structure than operational fundamentals, and further analysis of financial reports would be needed for a stronger stance.

Keywords

Bausch Health, BHC, Icahn Group, Paulson Capital, Board of Directors, Corporate Governance, Shareholding, SEC Filing, Pharmaceuticals, Bausch + Lomb